BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc. – The letter ‘K’ in the term vitamin K is derived from the Germanic word Koagulation.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Protein purification is a procedure, in which one or more proteins are extracted from a complex mixture, typically made up of cells or tissues.

According to the current analysis of Reports and Data, the global Apheresis Equipment market was valued at USD 1.62 Billion in 2018 and is expected to reach USD 2.98 Billion by year 2026, at a CAGR of 7.8%.

According to the current analysis of Reports and Data, the global Capsule Endoscopy market was valued at USD 0.60 Billion in 2018 and is expected to reach USD 1.30 Billion by year 2026, at a CAGR of 9.0 %.

Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced the appointment of David McCullough as Senior Director and Head of U.S. Market Access, effective August 22 nd.

Vicore Pharma Holding AB announces that the previously published interim data from AIR, a phase 2 trial in IPF), will be presented as an oral “late-breaker” on September 4 at 15:00 CET during the European Respiratory Society congress in Barcelona, Spain.

Gerresheimer AG and Zollner Elektronik AG are pooling their market-leading pharmaceutical and medical technology expertise under a strategic partnership.

Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, announced the pricing of an upsized underwritten public offering with gross proceeds of approximately $270 million.

Tessa Therapeutics Ltd. announced the dosing of the first patient in a Phase 1b clinical trial investigating TT11, the company’s autologous CD30 chimeric antigen receptor T-cell therapy, in combination with Bristol Myers Squibb’s nivolumab as a potential second-line treatment for patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma.